Buy sleeping pills like Lunesta and Melatonin – Expert advice

Lunesta  exhibits fewer anticholinergic side effects than racemic zopiclone. The following side effects may occur with Eszopiclone (Lunesta): Common side effects:

• unpleasant bitter or metallic taste in the mouth;
• headache;
• chest pain;
• symptoms of influenza;
• pain;
• dry mouth;
• daytime sleepiness;
• lightheadedness;
• dizziness;
• upset stomach;
• decreased libido;
• painful menstruation;
• heartburn;

Less common side effects may include:

• rash;
• itching;
• incoordination;
• swelling of the arms, legs, ankles, or lower legs;
• painful or frequent urination;
• back pain;

Neuropsychiatric side effects include:

• aggressive behavior;
• mental confusion;
• nervousness;
• auditory and visual hallucinations;
• worsening depression;
• suicidal thoughts;
• depersonalization; amnesia;

If a person does not fall asleep immediately after applying Lunesta or if he wakes up shortly after taking the drug, he may experience dizziness, faintness, hallucinations (see things or hear voices that do not exist), as well as problems with coordination and memory.

In the United States, Lunesta is on the list of IV controlled substances. The use of benzodiazepines and benzodiazepine-like drugs, such as eszopiclone, can lead to the development of physical and psychological dependence. The risk of abuse and dependence increases with increasing dose and duration of use and the use of other psychoactive substances. Patients with a history of alcohol or drug abuse or a history of mental disorders are also at increased risk. After repeated use of benzodiazepines and benzodiazepine drugs for several weeks, tolerance may develop. The effects of Lunesta was studied when taken for up to 6 months in a group of patients who showed no signs of tolerance or dependence during the study,

A study of the abuse potential of Lunesta showed that in individuals with a known history of benzodiazepine abuse, Lunesta in doses of 6 and 12 mg produces effects similar to 20 mg of diazepam . The study showed that when taking doses two or more times higher than the maximum recommended dose, there was a dose-dependent increase in reports of amnesia and hallucinations for both Eszopiclone (Lunesta) and Diazepam (Valium).

An overdose of Lunesta can be dangerous. Signs of Lunesta overdose include a dulling of the mental state, an increase in the threshold of coronary spasm sensitivity, troponemia, a slowing of ventricular fibrillation, and prolonged coma (up to 48 hours). Texas Toxicology Centers report that in all over 2005–2006, a total of 525 cases of Eszopiclone overdose were reported in the state of Texas, most of which are associated with intentional suicide attempts. If an hour does not pass after consuming Eszopiclone, overdose can be avoided by using activated charcoal or using a gastric probe.

Eszopiclone acts as an agonist on the benzodiazepine binding sites located on GABA-A neurons. Eszopiclone is rapidly absorbed after oral administration, serum levels peak after 1-1.3 hours after ingestion. The half-life of eszopiclone is approximately 6 hours. The substance is extensively metabolized by oxidation and demethylation. Approximately 52% to 59% of the dose is poorly bound to plasma proteins. CYP3A4 and CYP2E1 isoenzymes of cytochrome P450 (CYP) are involved in Esotropiclone biotransformation; thus, drugs that induce or inhibit these CYP isoenzymes can affect Lunesta metabolism. Less than 10% of the dose taken orally is excreted in the urine as racemic zopiclone.. In terms of benzodiazepine receptor binding and actual potency, 3 mg of Lunesta is equivalent to 10 mg of diazepam .

An article published in the New England Journal of Medicine in 2009 states that the largest of the three Lunesta trials found that Lunesta was “superior to placebo”, reducing the initial sleep time by an average of 15 minutes. “Doctors interested in the effectiveness of the drug will not be able to find information about its effectiveness on the label: it is only said that Lunesta is superior to placebo. FDA medical research provides efficacy data. In the largest and largest phase 3 trials, it was reported that patients from the Lunesta group fell asleep an average of 15 minutes faster and sleep lasted an average of 37 minutes longer than in the placebo group. On average, however, patients taking Lunesta did not report any clinically significant improvement the next day regarding activity or functioning. ”

On September 11, 2007, Sepracor signed a marketing agreement with the British pharmaceutical company GlaxoSmithKline for the rights to sell Lunesta (called Lunivia, not Lunesta) in Europe. It was expected that if the transaction was successful, Sepracor would receive about $ 155 million. In 2008, Sepracor submitted an application to EMA (equivalent to the US FDA in the European Union) to authorize rights to market the drug in the EU, and initially received a positive response. Sepracor, however, withdrew its application in 2009, after the EMA announced that it would not give Eszopiclone the status of “new active substance”, because it is too pharmacologically and therapeutically similar to zopiclone. Since the expired patent for Zopiclone, this solution would allow competing companies to also legitimately produce cheaper Lunesta generics for the European market. As of November 2012, Sepracor has not re-applied for the drug, and Lunesta / Lunivia is still not available for purchase in Europe. The deal with GSK also fell through, and GSK instead launched a $ 3.3 billion deal to sell Altelxant from Actelion, which entered the third phase of clinical trials before its development was halted due to side effects.